These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17519307)

  • 21. Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide.
    Thivolet C; Marchand L; Chikh K
    Diabetologia; 2019 Apr; 62(4):593-597. PubMed ID: 30612138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proinsulin, GLP-1, and glucagon are associated with partial remission in children and adolescents with newly diagnosed type 1 diabetes.
    Kaas A; Andersen ML; Fredheim S; Hougaard P; Buschard K; Petersen JS; de Beaufort C; Robertson KJ; Hansen L; Mortensen HB; Nielsen LB;
    Pediatr Diabetes; 2012 Feb; 13(1):51-8. PubMed ID: 22118630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses.
    Rijkelijkhuizen JM; McQuarrie K; Girman CJ; Stein PP; Mari A; Holst JJ; Nijpels G; Dekker JM
    Metabolism; 2010 Apr; 59(4):502-11. PubMed ID: 19846181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased active GLP-1 response following large test meal in patients with type 1 diabetes using bolus insulin analogues.
    Kamoi K; Shinozaki Y; Furukawa K; Sasaki H
    Endocr J; 2011; 58(10):905-11. PubMed ID: 21878743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test.
    Ito A; Horie I; Miwa M; Sako A; Niri T; Nakashima Y; Shigeno R; Haraguchi A; Natsuda S; Akazawa S; Kamada A; Kawakami A; Abiru N
    J Diabetes Investig; 2021 Aug; 12(8):1367-1376. PubMed ID: 33369175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
    Ellis SL; Moser EG; Snell-Bergeon JK; Rodionova AS; Hazenfield RM; Garg SK
    Diabet Med; 2011 Oct; 28(10):1176-81. PubMed ID: 21923696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolbutamide controls glucagon release from mouse islets differently than glucose: involvement of K(ATP) channels from both α-cells and δ-cells.
    Cheng-Xue R; Gómez-Ruiz A; Antoine N; Noël LA; Chae HY; Ravier MA; Chimienti F; Schuit FC; Gilon P
    Diabetes; 2013 May; 62(5):1612-22. PubMed ID: 23382449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
    Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
    Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
    Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormal late postprandial glucagon response in type 1 diabetes is a function of differences in stimulated C-peptide concentrations.
    Zhang L; Qin Y; Huang Y; Hu Q; Wu Q; Wang X; Zhang M
    Front Endocrinol (Lausanne); 2024; 15():1419329. PubMed ID: 39149119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incretin and islet hormone responses to meals of increasing size in healthy subjects.
    Alsalim W; Omar B; Pacini G; Bizzotto R; Mari A; Ahrén B
    J Clin Endocrinol Metab; 2015 Feb; 100(2):561-8. PubMed ID: 25375983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
    Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
    Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
    Rosenfalck AM; Thorsby P; Kjems L; Birkeland K; Dejgaard A; Hanssen KF; Madsbad S
    Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of residual β cell function in long-standing type 1 diabetes.
    Sherr JL; Ghazi T; Wurtz A; Rink L; Herold KC
    Diabetes Metab Res Rev; 2014 Feb; 30(2):154-62. PubMed ID: 24115337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of injection-meal interval usage and its association with variables of metabolic control in patients with Type 1 and Type 2 diabetes.
    Müller N; Kloos C; Frank T; Ristow M; Wolf G; Müller UA
    Diabet Med; 2011 Feb; 28(2):223-6. PubMed ID: 21219434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
    Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B
    Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of meal composition on postprandial glucagon-like peptide-1, insulin, glucagon, C-peptide, and glucose responses in overweight/obese subjects.
    Shah M; Franklin B; Adams-Huet B; Mitchell J; Bouza B; Dart L; Phillips M
    Eur J Nutr; 2017 Apr; 56(3):1053-1062. PubMed ID: 26759261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
    Hollander P; Li J; Allen E; Chen R;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4810-9. PubMed ID: 19864452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.